Spyre Therapeutics, Inc. (SYRE)
NASDAQ: SYRE · Real-Time Price · USD
88.98
+1.73 (1.98%)
Sep 4, 2026, 4:00 PM EDT - Market closed
Spyre Therapeutics Stock Forecast
Stock Price Forecast
According to 17 analysts polled by S&P Global, Spyre Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $119.71. The average 1-year stock price forecast is 34.54% higher than the current stock price, while the lowest is $97 (+9.01%) and the highest is $130 (+46.10%).
Price Target: $119.71 (+34.54%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Spyre Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 16 | 17 | 17 | 17 | 16 | 16 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 16 | 17 | 17 | 17 | 17 | 17 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| LifeSci Capital | LifeSci Capital | Buy Maintains $129 → $116 | Buy | Maintains | $129 → $116 | +30.37% | Aug 29, 2026 |
| Guggenheim | Guggenheim | Buy Reiterates $130 | Buy | Reiterates | $130 | +46.10% | Aug 27, 2026 |
| JonesTrading | JonesTrading | Buy Reiterates $140 → $121 | Buy | Reiterates | $140 → $121 | +35.99% | Aug 26, 2026 |
| Wedbush | Wedbush | Buy Maintains $130 → $123 | Buy | Maintains | $130 → $123 | +38.23% | Aug 26, 2026 |
| BTIG | BTIG | Buy Reiterates $132 → $121 | Buy | Reiterates | $132 → $121 | +35.99% | Aug 26, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-2.83
from -1.98
EPS Next Year
-3.43
from -2.83
EPS and Forward PE are based on non-GAAP adjusted numbers.